Back to Directory

Katie McCarthy

Email

kmccarthy@fhi360.org

Phone

(919) 321-3326

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2041: Phase IV Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir (GLE/PIB) in People with Hepatitis C During Pregnancy and Postpartum

DAIDS Number

Research Area

Complications & Comorbidities

IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

Research Area

Study Status

1077FF: PROMISE 1077FF

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

Research Area

P1084s: Maternal Infant TDF Toxicity Safety

DAIDS Number

Research Area

Complications & Comorbidities

Study Status

Closed to Follow Up

Show All